Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TDA vs Schwab - another nice feature we're evidently losing is the earnings calendar for positions held and watchlists. It's very convenient to look at the monthly calendar and see at a glance how many positions are scheduled to report on any given day. Then click on the day to get the detailed earnings estimates for each company and also what they reported if the date has passed ....
Schwab's website is primitive compared to Ameritrade's, imho.
RMAX +.75 to 9.48 after reporting the completion of the settlement agreement - notably, the company does not expect an impact to its operating results or cash flows -
8K -
Under the Settlement Agreement, RE/MAX agreed to pay a total settlement amount of $55.0 million (the “Settlement Amount”) into a qualified settlement fund. RE/MAX paid one half of the Settlement Amount?during 2023 and expects to pay the remaining half within ten business days of the District Court’s final approval of the Settlement Agreement. In 2023, the Company recorded?a pre-tax charge for the full Settlement Amount within its Consolidated Statements of Income (Loss) with a corresponding liability recorded to accrued liabilities within its Consolidated Balance Sheets. In addition, RE/MAX agreed to make certain previously disclosed changes to its business practices. Apart from the payment of the Settlement Amount, the Company does not expect the terms of the Settlement Agreement to have a material impact on its results of operations and cash flows.
I'll soon be giving Schwab a call with my complaints, but I think it will fall on deaf ears.
I will definitely be evaluating Fidelity and Etrade as an alternative to Schwab .... the Schwab website is not trader friendly compared to Ameritrade. Very cumbersome for someone who enters many trades each day.
If I do shift business to another broker, I don't transfer the account .... I don't want it to be in limbo for several days or longer. Instead I flag it as sell only and periodically transfer the cash .....
TDA vs Schwab ..... I often have 40+ open orders at any given time since I like to scale in and out of numerous positions to profit from volatility. At TDA one can very efficiently sort orders by limit price, size, etc ..... any column is sortable, but not at Schwab .... also at TDA one can cancel orders very quickly, 10 or more at a time by clicking the box by each order or one can cancel all orders for a single security with one click. At Schwab it's very tedious to cancel a lot of orders based on what I'm seeing. It's one at a time. Ugh.
Schwab order entry is more tedious than at Ameritrade ..... I often like to enter a stack of small orders at different price points .... at Ameritrade one can click "reuse" on open or filled orders to generate a duplicate, then just change the price and submit. On Schwab it seems that there is no "reuse" feature and each order must be entered separately. And one has to acknowledge that it's similar to an existing order. A lot more clicks and trade ticket edits overall.
AAOI +.33 to 10.87, after hitting a high of 11.86 ..... the conf call was bullish on the 2nd half of 2024 and they expect an overall profitable year on an adj EPS basis .... that implies adj EPS of up to $0.60+ for the 2nd half, but that remains to be seen -
Conf Call -
With the improvement we expect in the second half, we continue to believe that 2024 can be our first full year of non-GAAP profitability since 2018.
AAOI down 20% after hours on lousy earnings and Q2 guidance ....
https://finance.yahoo.com/news/applied-optoelectronics-reports-first-quarter-201000875.html
RIOT -.12 to 10.23, I opened a small trading position in this bitcoin miner today. Q1 EPS was $0.82 thanks to a big mark to market gain in their bitcoin holdings. Obviously they'll see big fluctuations in quarterly earnings/losses as bitcoin prices move up and down. It's a volatile stock with very high weekly option premiums, so primarily I'm interested in capturing the premiums by writing covered calls and naked puts. The 52wk high is $20.65 and the chart shows technical support at around $10.
https://finance.yahoo.com/news/riot-platforms-reports-first-quarter-120000538.html
DIN -.14 to 43.44, after an earnings miss, but guidance maintained. Any thoughts ?
briefing -
Dine Brands misses by $0.24, misses on revs; reaffirms FY24 domestic comp guidance (43.55 ) :
Reports Q1 (Mar) earnings of $1.33 per share, excluding non-recurring items, $0.24 worse than the FactSet Consensus of $1.57; revenues fell 3.5% year/year to $206.24 mln vs the $210.54 mln FactSet Consensus.
Applebee's domestic comparable same-restaurant sales declined -4.6% in Q1.
IHOP's domestic comparable same-restaurant sales declined -1.7% i Q1.
Co reaffirms FY24 domestic comp guidance: Applebee's at +0-2%; IHOP at +1-3%.
"Our brands have been tested through many economic cycles in the past decades and while our first quarter results reflect the impact of consumer price sensitivity and challenging weather conditions, our fundamental business model remains steady with solid cash flow and positioning us to deliver on our guidance for the year."
IDR +.24 to 9.35, nice trading .... I'm holding on for now, averaged in at $8.67 .....
HALO +1.24 to 42.45 after hitting 44.78 earlier this morning ..... I'm holding on to my shares but wrote some June $45 calls at $1.50 .... but I wouldn't be surprised if it dips back into the high $30's at some point especially if there's a major market correction this summer.
HALO (41.21) beats Q1 estimates by 14% and maintains annual guidance -
briefing -
Halozyme Therapeutics beats by $0.10, misses on revs; reaffirms FY24 EPS guidance, revs guidance (41.21 +0.35) :
Reports Q1 (Mar) earnings of $0.79 per share, excluding non-recurring items, $0.10 better than the FactSet Consensus of $0.69; revenues rose 20.8% year/year to $195.88 mln vs the $199.74 mln FactSet Consensus.
Co reaffirms guidance for FY24, sees EPS of $3.55-3.90, excluding non-recurring items, vs. $3.52 FactSet Consensus; sees FY24 revs of $915-985 mln vs. $954.43 mln FactSet Consensus.
Announced new $750 million share repurchase program in February.
Schwab - ok I just bought a few tiny positions at Schwab ahead for my transfer from Ameritrade. I see the cost basis shown by lot. Also the account settings provide the tax lot optimizer for lot selection. Ameritrade has displays by Realized Gain/Loss, Unrealized and Pending Settlement. In pending settlement one can override the automated tax lot selection. I hope Schwab also offers this override feature. I'll be looking for it when I make my first sale .....
SSK - does Schwab have a cost basis display for portfolio holdings by lot ? At Ameritrade one can click on a security to see each purchase date, the lot size and gain or loss. One can also choose specific lots for sales for tax purposes.
Are these feature offered by Schwab ???
IART - I think it will be range bound in the mid to high $20's for the coming few months. Management has lost credibility and sentiment has changed from bullish to bearish on the stock.
IART +1.66 to 24.80 .... here are the analyst comments, fwiw - the price target cuts are rather severe.
fly -
Integra LifeSciences price target lowered to $25 from $37 at Truist
Truist analyst Richard Newitter lowered the firm's price target on Integra LifeSciences to $25 from $37 and keeps a Hold rating on the shares. The firm is adjusting its model to reflect the company's further Boston facility restart delay, also removing its previously modeled contributions, the analyst tells investors in a research note. Integra's Acclarent revenue offset the impact on the top line but not on margins, the firm states, adding that the stock's valuation discount is justified given the accumulating execution errors on the part of the company as well as its peers' faster revenue and growth prospects.
08:25 EDT IART
Integra LifeSciences price target lowered to $24 from $37 at Morgan Stanley
Morgan Stanley lowered the firm's price target on Integra LifeSciences to $24 from $37 and keeps an Underweight rating on the shares. An overall in line Q1 was "overshadowed" by another negative update on Boston facility commercialization, says the analyst, who continues to see Integra shares underperforming relative to peers over the next 12 months.
06:56 EDT IART
Integra LifeSciences price target lowered to $40 from $49 at JMP Securities
JMP Securities analyst David Turkaly lowered the firm's price target on Integra LifeSciences to $40 from $49 and keeps an Outperform rating on the shares following the Q1 results. Management noted that a third-party audit was recently conducted at its Boston facility, and the observations extended the expected relaunch timeframe for SurgiMend, PriMatrix, and several private label lines indefinitely, the analyst tells investors in a research note. While the magnitude of the financial update was not that significant, it is likely the open-ended nature of the situation from a timing standpoint that sent the stock down 20%, which JMP views as overdone.
06:45 EDT IART
Integra LifeSciences price target lowered to $26 from $42 at BofA
BofA lowered the firm's price target on Integra LifeSciences to $26 from $42 and keeps an Underperform rating on the shares. Integra does not expect to get its Boston facility back online in 2024 and the new findings from the Boston audit "are the latest in a series of setbacks" over the last two years, says the analyst, who adds that "investors have grown increasingly frustrated amidst the numerous delays." The company's updated FY24 sales guidance "looks too aggressive" and implies a second half sales ramp that "may be hard to hit," the analyst contends.
Integra LifeSciences price target lowered to $25 from $45 at Wells Fargo
Integra LifeSciences downgraded at Wells on pushout of Boston facility restart
As previously reported, Wells Fargo downgraded Integra LifeSciences to Equal Weight from Overweight with a price target of $25, down from $45. The firm had previously upgraded Integra as it had believed that the Boston facility restart would represent an inflection point and drive potential EPS upside from a return of high margin products. However, management noted that it no longer expects to resume Boston commercial distribution in 2024 as the third party audit yielded more findings than expected and more work is needed. Given that restart is not expected in 2024 and management is still working on a detailed plan without a specific timeline offered, the firm is moving to the sidelines, the analyst tells investors.
IART - maybe traders were in the stock in anticipation of good news about Boston .... they didn't get so now they are dumping. If so, it could get a bounce once the traders have finished selling. Maybe some analyst upgrades will be forthcoming based on price.
IART -5.57 to 23.32, evidently the market is viewing the earnings adjustments conservatively as I am .... not generously as you are. Good luck. It does look technically oversold and might get a decent bounce this afternoon or in the coming days ..... in which case I'd be a seller.
I highly doubt IART will get bought out at a huge premium, but good luck. HZNP doesn't change my view on what expenses are legitimate and should not be adjusted out. I don't recall the HZNP details, but maybe the company had strong growth prospects which IART does not. I would be shocked if IART gets bought out at a big premium. The business prospects don't justify it.
IART reports a HUGE difference between GAAP and adjusted EPS. For Q1 GAAP EPS was a loss of (0.04) while adjusted EPS was $0.55.
Are the adjustments all legitimate ? I think not. Just taking a quick look, amortization of intangibles is a recurring real expense for acquired assets that have a limited market life. It's analogous to depreciation expense and should not be ignored. The cash outflow flow occurs at the time of acquisition, but the expense occurs as the remaining life of the asset diminishes. It's not a free ride !
And other expense like recurring EU regulatory charges shouldn't be adjusted out either ....
So in conclusion, the forward PE is MUCH higher when one gets less generous with the GAAP to non-GAAP adjustments. I'm not so generous with the adjustments and evidently the market isn't either.
Wade - IART - are you doubling down at $24.80 ???
IART -3.74 to 25.15, clearly the market is not happy with the earnings and guidance .... I remain on the sidelines.
IDR +1.19 to 8.80, benefiting from soaring gold prices. I joined you with a few shares. Thanks for the earnings alert. Q2 earnings should be even better. Earnings untaxed for now, not sure how long that will last, need to check the 10K for operating loss carry forwards.
Thanks to everyone for the congratulations and good luck in the upcoming contest !
RMAX +1.55 to 8.71 after a slight earnings beat ...... evidently traders were expecting a big miss. I trimmed some shares, but will buy back lower if there's a big pullback.
briefing -
RE/MAX Holdings beats by $0.01, reports revs in-line; guides Q2 revs in-line; guides FY24 revs in-line (7.16 -0.04) :
Reports Q1 (Mar) earnings of $0.20 per share, excluding non-recurring items, $0.01 better than the FactSet Consensus of $0.19; revenues fell 8.3% year/year to $78.29 mln vs the $77.75 mln FactSet Consensus.
Co issues in-line guidance for Q2, sees Q2 revs of $75-80 mln vs. $78.58 mln FactSet Consensus.
Co issues in-line guidance for FY24, sees FY24 revs of $300-320 mln vs. $310.66 mln FactSet Consensus.
Fed rate cut probabilities went up as bond rates fell on the weaker than expected jobs report. Goldilocks !
S&P futures surge 55 points higher after a weaker than expected April Jobs Report -
https://www.cnbc.com/2024/05/02/stock-market-today-live-updates.html
Glad you did well with AESI .... I've also been trimming my O&G related holdings. Oil prices may continue to slowly trend lower as suggested by the backwardation of the futures market .....
SBOW, VTLE
SBOW looks like a strong quarter .... adj EPS of $2.09 beat analyst estimates for $1.58. Free cash flow was strong allowing a pay down of debt. The derivative loss was expected since crude oil prices rose from $72 at year end to $83 on 3/31/24, hence the mark to market writedown of their future period hedging position.
The big wildcard remains oil prices which have been falling recently -
https://oilprice.com/Latest-Energy-News/World-News/Oil-Prices-Plummet-3-on-US-Inventory-Build-Inflation.html
Market Commentary -
briefing -
Going into Fed Chair Powell's press conference, the market was nervous about the possibility of Fed Chair Powell sounding more hawkish than he did at the March FOMC press conference. The key thought around that nervous feeling was that Fed Chair Powell would connote the notion that it is increasingly possible that the Fed will elect to raise rates further.
He said (and we quote): "I think it's unlikely that the next policy rate move will be a hike. I would say it's unlikely."
The fact that the stock market and the Treasury market rallied initially on that acknowledgment should come as no surprise. It was (relief) music to their ears.
From our vantage point, Fed Chair Powell worked hard to shoot down the prospect of another rate hike, sticking instead to the view that the Fed will stick with its current policy stance as long as it is appropriate and that a path to cutting rates would follow inflation moving sustainably towards the Fed's 2% target or an unexpected weakening in the labor market.
Fed Chair Powell clarified that a couple of tenths higher in the unemployment rate itself would probably not qualify as a meaningful weakening in the labor market.
By and large, the Fed seems stuck with its current policy stance, which is a byproduct of economic data for a data-dependent Fed that has occasionally run hot, has oftentimes run warm, and has rarely turned cold. Accordingly, it keeps the Fed guessing like the rest of us if the policy stance is truly appropriate or will be revealed in hindsight to be too restrictive or not restrictive enough.
The Fed Chair is convinced that the evidence shows pretty clearly that policy is restrictive and is weighing on demand; however, gaining greater confidence in inflation moving sustainably toward 2%, he said, will take longer than previously expected.
So, the market is stuck with the uncertainty of how long the current policy rate will be in effect, which means it will be stuck with higher rates for longer as an uncertain Fed tries to understand if it has done enough, or needs to do more, to get inflation back to 2%.
The Russell 2000 is up 1.5%; the Dow Jones Industrial Average is up 0.7%; the Nasdaq Composite is up 0.5%; and the S&P 500 is up 0.2%.
SBOW - here's the stock price history compared to crude oil .... they do a lot of hedging so may fetch above or below market prices in any given quarter -
Date SBOW Oil
20230103 24.99 76.93
20230104 25.84 72.84
20230105 25.92 73.67
20230106 26.17 73.77
20230109 26.51 74.63
20230110 26.28 75.12
20230111 26.01 77.41
20230112 27.54 78.39
20230113 27.37 79.86
20230117 27.85 80.45
20230118 26.4 79.8
20230119 27.01 80.61
20230120 26.74 81.64
20230123 27.56 81.62
20230124 26.17 80.13
20230125 26.54 80.15
20230126 26.76 81.01
20230127 26.68 79.68
20230130 25.26 77.9
20230131 26.27 78.87
20230201 25.09 76.41
20230202 24.73 75.88
20230203 24.37 73.39
20230206 23.48 74.11
20230207 24.75 77.14
20230208 23.98 78.47
20230209 23.24 78.06
20230210 25.42 79.72
20230213 25.46 80.14
20230214 25.83 79.06
20230215 25.64 78.83
20230216 25.52 78.74
20230217 23.77 76.55
20230221 22.64 76.36
20230222 22.88 73.95
20230223 23.51 75.39
20230224 24.84 76.32
20230227 24.94 75.68
20230228 24.62 77.05
20230301 25.45 77.69
20230302 28.86 78.16
20230303 29.38 79.68
20230306 27.3 80.46
20230307 26.15 77.58
20230308 25.92 76.66
20230309 24.82 75.72
20230310 23.63 76.68
20230313 22.59 74.8
20230314 22.42 71.33
20230315 21.61 67.74
20230316 21.88 68.52
20230317 20.98 66.93
20230320 21 67.82
20230321 21.84 69.67
20230322 20.49 70.9
20230323 20.31 69.96
20230324 20.57 69.26
20230327 22.21 72.81
20230328 22.26 73.2
20230329 22.25 72.97
20230330 22.17 74.37
20230331 22.85 75.67
20230403 24.35 80.42
20230404 23.85 80.71
20230405 24.13 80.61
20230406 23.36 80.7
20230410 23.8 79.74
20230411 25.58 81.53
20230412 25.55 83.26
20230413 25.51 82.16
20230414 25.21 82.52
20230417 24.63 80.83
20230418 24.44 80.9
20230419 24.01 79.24
20230420 23.13 77.37
20230421 23.02 77.87
20230424 24.17 78.76
20230425 22.84 77.07
20230426 22.15 74.3
20230427 22.44 74.76
20230428 23.85 76.78
20230501 23.57 75.66
20230502 21.95 71.66
20230503 21.91 68.6
20230504 21.85 68.56
20230505 22.6 71.34
20230508 22.63 73.16
20230509 23.09 73.71
20230510 22.99 72.56
20230511 22.93 70.87
20230512 23.62 70.04
20230515 24.14 71.09
20230516 23.17 70.84
20230517 24.11 72.89
20230518 24.81 71.94
20230519 24.38 71.69
20230522 25.12 72.05
20230523 25.17 72.91
20230524 25.06 74.34
20230525 23.99 71.83
20230526 23.57 72.67
20230530 23.33 69.46
20230531 23.88 68.09
20230601 24.03 70.1
20230602 25.79 71.74
20230605 25.27 72.15
20230606 26.3 71.74
20230607 27 72.53
20230608 26.93 71.29
20230609 26.74 70.17
20230612 25.85 67.12
20230613 26.63 69.42
20230614 26.11 68.27
20230615 26.73 70.81
20230616 27.13 71.93
20230620 26.65 71.19
20230621 27.09 72.53
20230622 26.42 69.51
20230623 25.45 69.16
20230626 26.55 69.37
20230627 27.1 67.7
20230628 28.51 69.56
20230629 28.95 69.86
20230630 29.12 70.64
20230703 28.95 69.79
20230705 28.33 71.79
20230706 27.27 71.8
20230707 29.06 73.86
20230710 29.71 72.99
20230711 31.05 74.83
20230712 30.86 75.75
20230713 31.04 76.89
20230714 29.29 75.42
20230717 29.65 74.08
20230718 31.3 75.66
20230719 31.05 75.29
20230720 31.31 75.65
20230721 31.82 77.07
20230724 32.58 78.74
20230725 33.54 79.63
20230726 33.71 78.78
20230727 33.63 80.09
20230728 34.83 80.58
20230731 35.81 81.8
20230801 34.74 81.37
20230802 34.06 79.49
20230803 36.66 81.55
20230804 37.01 82.82
20230807 38.91 81.94
20230808 39.64 82.92
20230809 39.94 84.4
20230810 39.44 82.82
20230811 39.36 83.19
20230814 41.53 82.51
20230815 40.47 80.5
20230816 39.91 79.02
20230817 41 79.9
20230818 40.94 80.66
20230821 41.99 80.12
20230822 41.61 79.64
20230823 41.83 78.89
20230824 41.45 79.05
20230825 41.79 79.83
20230828 41.9 80.1
20230829 41.7 81.16
20230830 42.13 81.63
20230831 42.78 83.63
20230901 42.6 85.55
20230905 41.95 86.69
20230906 41.8 87.54
20230907 41.99 86.87
20230908 42.12 87.51
20230911 40.99 87.29
20230912 42.16 88.84
20230913 38.48 88.52
20230914 36.64 90.16
20230915 35.02 90.02
20230918 35.65 90.58
20230919 35.36 90.48
20230920 34.4 89.66
20230921 33.02 89.63
20230922 32.91 90.03
20230925 34 89.68
20230926 34.41 90.39
20230927 35.6 93.68
20230928 36.51 91.71
20230929 35.77 90.79
20231002 33.39 88.82
20231003 33.19 89.23
20231004 31.19 84.22
20231005 30.98 82.31
20231006 32 82.79
20231009 32.98 86.38
20231010 34.15 85.97
20231011 33.17 83.49
20231012 33.46 82.91
20231013 34.6 87.69
20231016 35.54 85.26
20231017 36 85.44
20231018 36.27 87.27
20231019 35.84 88.37
20231020 35.26 88.08
20231023 35.23 85.49
20231024 34.51 83.74
20231025 34.15 85.39
20231026 34.1 83.21
20231027 33.53 85.54
20231030 33.57 82.31
20231031 34.1 81.02
20231101 33.48 80.44
20231102 36.36 82.46
20231103 36.45 80.51
20231106 34.25 80.82
20231107 33.15 77.37
20231108 32.57 75.33
20231109 32.08 75.74
20231110 31.9 77.17
20231113 31.9 78.26
20231114 32.5 78.26
20231115 32.52 76.79
20231116 31.44 73.09
20231117 31.8 76.04
20231120 32.39 77.83
20231121 31.99 77.77
20231122 32.36 77.1
20231124 32.46 75.54
20231127 31.53 74.86
20231128 31.58 76.41
20231129 31.81 77.86
20231130 31.81 75.96
20231201 32.1 74.07
20231204 32.6 73.04
20231205 31.3 72.32
20231206 29.31 69.38
20231207 29.59 69.34
20231208 30.55 71.23
20231211 29.95 71.32
20231212 27.35 68.61
20231213 28.14 69.47
20231214 28.55 71.58
20231215 28.53 71.78
20231218 28.36 72.82
20231219 28.59 73.94
20231220 28.02 74.22
20231221 28.62 73.89
20231222 28.83 73.56
20231226 29.62 75.57
20231227 29.11 74.11
20231228 28.75 71.77
20231229 29.08 71.65
20240102 28.61 70.38
20240103 29.1 72.7
20240104 28.16 72.19
20240105 28.1 73.81
20240108 27.86 70.77
20240109 27.39 72.24
20240110 27.22 71.37
20240111 27.28 72.02
20240112 27.5 72.68
20240116 26.21 72.52
20240117 25.84 72.48
20240118 25.87 73.95
20240119 25.7 73.25
20240122 26.14 74.76
20240123 26.35 74.37
20240124 26.82 75.09
20240125 27.64 77.36
20240126 27.36 78.01
20240129 27.19 76.78
20240130 27.8 77.82
20240131 26.56 75.85
20240201 26.31 73.82
20240202 26.19 72.28
20240205 25.99 72.78
20240206 26.44 73.31
20240207 26.54 73.86
20240208 27.21 76.22
20240209 26.54 76.84
20240212 27.49 76.92
20240213 26.34 77.87
20240214 26.13 76.64
20240215 27.7 77.59
20240216 27.91 78.46
20240220 27.49 77.04
20240221 28.05 77.91
20240222 28.1 78.61
20240223 27.43 76.49
20240226 27.64 77.58
20240227 28.59 78.87
20240228 28.45 78.54
20240229 28.39 78.26
20240301 29.79 79.97
20240304 29.48 78.74
20240305 30.73 78.15
20240306 30.66 79.13
20240307 30.56 78.93
20240308 30.77 78.01
20240311 31.34 77.93
20240312 31.72 77.56
20240313 31.94 79.72
20240314 33.41 81.26
20240315 33.92 80.58
20240318 35.15 82.16
20240319 35.45 82.73
20240320 34.97 81.27
20240321 34.75 81.07
20240322 34.67 80.63
20240325 35.34 81.95
20240326 34.43 81.62
20240327 34.69 81.35
20240328 34.14 83.17
20240401 34.36 83.71
20240402 34.47 85.15
20240403 34.42 85.43
20240404 33.92 86.59
20240405 33.77 86.91
20240408 33.89 86.43
20240409 34.44 85.23
20240410 34.82 86.21
20240411 33.82 85.02
20240412 33.07 85.66
20240415 32.35 84.86
20240416 31.84 84.83
20240417 30.01 82.15
20240418 29.67 82.1
20240419 30.06 82.22
20240422 30.15 81.9
20240423 30.53 83.36
20240424 30.74 82.81
20240425 31.45 83.57
20240426 32.03 83.85
20240429 33.18 82.63
20240430 30.72 81.93
FISI +.42 to 17.64, thanks for that in depth post. I joined you with a few shares and have some GTC buy orders placed at lower prices ....
SBOW -.73 to 29.99, the culprit behind the recent weakness is falling crude oil prices, now under $80/bbl, down from near $88 just 3 weeks ago ..... NG prices have also been weak due to a supply glut.
SMCI has a market cap of $50B, HPE is a mere $22B while DELL is $88B ....
HPE, Hewlett Packard Enterprises, has a forward PE of only around 9, so if they snatch some market share from SMCI and become viewed as an AI server growth story, the stock could see a lot of multiple expansion.
SMCI - as I posted a few weeks ago, the AI server business has lower barriers to entry than the AI chip design business - SMCI will be experiencing increasing margin pressure in the coming months. The stock could be a good short term trader, but not a long term hold, imho.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173852229&txt2find=dell
DELL, HP
SMCI after hours range is now 797 to 947 .... with the stock currently at 858. Crazy action over just a few minutes! Who knows where it settles ???
SMCI +77 to 935 after hours after a solid earnings beat and strong guidance .....
INMD -.09 to 17.14, looks oversold. I just added a few shares and sold the June $17.5 Calls for $1.25, so my cost basis on this purchase is around $15.90. Seems like a bargain. Earnings are due out Thursday morning.
SMCI -35 to 855 ahead of the earnings after the bell. Option premiums imply a mean expected move of $121 up or down on the news .... should be interesting.